Newsfeeds - Spark Newswire

1 minute read

Vertex Pharmaceuticals Q4 EPS $3.37 Beats $3.29 Estimate, Sales $2.07B Beat $2.00B Estimate

Today, 8:52 PM

Vertex Pharmaceuticals (NASDAQ:VRTX) reported quarterly earnings of $3.37 per share which beat the analyst consensus estimate of $3.29 by 2.43 percent. This is a 34.26 percent increase over earnings of $2.51 per share

VRTX

7 minute read

Earnings Scheduled For January 26, 2022

By Benzinga Insights

Today, 8:52 PM

Companies Reporting Before The Bell • Blue Foundry (NASDAQ:BLFY) is projected to report earnings for its fourth quarter.

ABT

2 minute read

The Week Ahead In Biotech (Jan 23-29): Roche, Azurity FDA Decisions, J&J, Vertex Earnings, Samsara Vision IPO And More

By Shanthi Rexaline

Today, 8:52 PM

Biotech stocks pulled back yet again during the week ending Jan. 21, with the sector retreating along with the broader market. The news flow tapered off following the frenetic pace of the week that encompassed the JPM Healthcare conference.

ABT

2 minute read

Analyst Ratings

Where Vertex Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 8:52 PM

Over the past 3 months, 6 analysts have published their opinion on Vertex Pharmaceuticals (NASDAQ:VRTX) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

VRTX

13 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For January 20, 2022

By Benzinga Insights

Today, 8:52 PM

Upgrades

AAT

1 minute read

BMO Capital Upgrades Vertex Pharmaceuticals to Outperform, Raises Price Target to $274

By Benzinga Newsdesk

Today, 8:52 PM

BMO Capital analyst Evan Seigerman upgrades Vertex Pharmaceuticals (NASDAQ:VRTX) from Market Perform to Outperform and raises the price target from $202 to $274.

VRTX

2 minute read

Benzinga Asks: Which ARK Fund Would You Rather Buy And Hold For 5 Years?

By Chris Katje

Today, 8:52 PM

One of the best-known and well-covered ETF companies over the past five years has been ARK Invest, led by Cathie Wood. With the funds falling over the past year and hitting new lows, Benzinga asked which fund would be favored to buy and hold.

ARKF